Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Rating of "Reduce" by Analysts

Key Points

• Medpace Holdings, Inc. has received an average analyst rating of "Reduce," with three sell ratings, twelve hold ratings, and two buy ratings among seventeen firms covering the company.
• Following its quarterly earnings report, Medpace reported $3.10 EPS, exceeding estimates, alongside a revenue of $603.31 million, reflecting a 14.2% year-over-year growth.
• Insider selling has raised concerns, with CEO August J. Troendle selling 36,196 shares and directors making notable stock transactions, reflecting a 3.76% decrease in the CEO's ownership.

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have earned a consensus recommendation of "Reduce" from the seventeen ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $424.10.

Several equities analysts recently commented on the company. Robert W. Baird boosted their price target on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Rothschild & Co Redburn lowered Medpace from a "buy" rating to a "neutral" rating and boosted their price target for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Truist Financial boosted their price target on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Zacks Research lowered Medpace from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Finally, Mizuho upped their target price on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research report on Friday, July 25th.

Medpace Stock Performance

Medpace stock opened at $527.40 on Tuesday. The stock's 50 day moving average price is $485.22 and its 200 day moving average price is $376.83. The firm has a market capitalization of $14.81 billion, a PE ratio of 39.21, a price-to-earnings-growth ratio of 3.14 and a beta of 1.40. Medpace has a one year low of $250.05 and a one year high of $547.15.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace's revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, analysts forecast that Medpace will post 12.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO August J. Troendle sold 36,196 shares of Medpace stock in a transaction on Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the sale, the chief executive officer owned 925,799 shares in the company, valued at approximately $440,587,744.10. The trade was a 3.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of Medpace stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director owned 10,197 shares of the company's stock, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by insiders.

Institutional Trading of Medpace

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Portside Wealth Group LLC lifted its holdings in shares of Medpace by 2.5% during the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company's stock valued at $342,000 after acquiring an additional 27 shares during the period. M&T Bank Corp lifted its holdings in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company's stock valued at $295,000 after acquiring an additional 31 shares during the period. Whittier Trust Co. lifted its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after acquiring an additional 35 shares during the period. PDS Planning Inc lifted its holdings in shares of Medpace by 1.5% during the second quarter. PDS Planning Inc now owns 2,421 shares of the company's stock valued at $760,000 after acquiring an additional 35 shares during the period. Finally, Front Row Advisors LLC lifted its holdings in shares of Medpace by 0.4% during the second quarter. Front Row Advisors LLC now owns 9,441 shares of the company's stock valued at $2,963,000 after acquiring an additional 35 shares during the period. Institutional investors own 77.98% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.